Intelligence Platform

Patents

Browse 379 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11306315

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306316

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286486

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286482

Endosomal cleavable linkers

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11261447

Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11246933

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229663

Serum amyloid P component (APCS) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207342

High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11198872

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11198876

Compositions and methods for inhibiting expression of TMPRSS6 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186842

Complement component iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11162098

Complement component C5 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11149276

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of u

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11149273

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gen

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11142766

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11136582

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11130953

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110174

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11079379

Methods of treating transthyretin (TTR) mediated amyloidosis

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11071784

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066670

Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11060091

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11052103

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of u

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053495

Multi-targeted single entity conjugates

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted